Updated:
Medidata Solutions
Medidata Solutions provides a unified clinical trial platform used in 90% of FDA novel drug approvals in 2025, processing billions of data points annually.
Medidata Solutions
Medidata powers smarter clinical trials with unified data, AI-driven insights, and patient-centric technology to accelerate research.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
San Francisco, United States · Tokyo, Japan · London, United Kingdom
Sector focus
Frequently asked questions
Who are Medidata's primary customers?
Medidata serves pharmaceutical sponsors, contract research organizations (CROs), and clinical sites. Named customers include ICON, Worldwide Clinical Trials, and Everest Clinical Research (per the firm, 2025).
What investment stages does Medidata's platform cover?
Medidata's platform covers the full clinical trial lifecycle, from study design and patient recruitment through data collection, regulatory submission, and post-approval. It supports Phase I through Phase IV trials.
Does Medidata offer AI capabilities?
Yes. Medidata provides AI-powered analytics, including an AI imaging solution and synthetic control arms. Its 2025 AI report found 72.9% of early adopters saw reduced study timelines (per the firm, 2025).
How is Medidata related to the pharmaceutical industry?
Medidata is a technology provider, not a drug developer. Its software is used by drug sponsors and CROs to manage and accelerate clinical trials. The platform was used in 90% of FDA novel drug approvals in 2025 (per the firm, 2025).
What therapeutic areas does Medidata specialize in?
Medidata supports trials across therapeutic areas including oncology, rare disease, central nervous system disorders, and cardiovascular disease. Its platform is agnostic to therapy area.
Which regions does Medidata operate in?
Medidata has offices in New York, San Francisco, Tokyo, and London. Its platform is used globally, with support for English, Japanese, Chinese, and Korean languages.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: